 Paul Norman
Concepts (756)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 60 | 2025 | 110 | 10.090 |
Why?
| | Killer Cells, Natural | 56 | 2025 | 469 | 6.850 |
Why?
| | Haplotypes | 44 | 2025 | 490 | 4.200 |
Why?
| | HLA Antigens | 22 | 2026 | 225 | 3.940 |
Why?
| | Alleles | 49 | 2026 | 881 | 3.820 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 36 | 3.410 |
Why?
| | Histocompatibility Antigens Class I | 17 | 2024 | 202 | 3.330 |
Why?
| | HLA-B Antigens | 21 | 2025 | 57 | 2.940 |
Why?
| | HLA-C Antigens | 19 | 2024 | 36 | 2.910 |
Why?
| | Polymorphism, Genetic | 32 | 2024 | 612 | 2.510 |
Why?
| | Genotype | 38 | 2025 | 1835 | 2.250 |
Why?
| | Receptors, KIR3DL1 | 13 | 2024 | 20 | 2.180 |
Why?
| | Selection, Genetic | 13 | 2026 | 256 | 2.090 |
Why?
| | Immunogenetics | 5 | 2024 | 7 | 2.010 |
Why?
| | Receptors, KIR2DL1 | 12 | 2024 | 21 | 1.990 |
Why?
| | Evolution, Molecular | 18 | 2022 | 515 | 1.680 |
Why?
| | Genetic Variation | 19 | 2025 | 984 | 1.320 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 550 | 1.310 |
Why?
| | Amyotrophic Lateral Sclerosis | 7 | 2026 | 99 | 1.260 |
Why?
| | HLA-A Antigens | 11 | 2023 | 52 | 1.250 |
Why?
| | Humans | 216 | 2026 | 144957 | 1.240 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 7 | 1.200 |
Why?
| | Employment | 4 | 2025 | 188 | 1.170 |
Why?
| | Receptors, Immunologic | 10 | 2021 | 206 | 1.100 |
Why?
| | Socioeconomic Factors | 8 | 2024 | 1327 | 1.070 |
Why?
| | Gene Flow | 3 | 2026 | 85 | 1.030 |
Why?
| | Health Status Disparities | 6 | 2024 | 321 | 1.020 |
Why?
| | Qualitative Research | 12 | 2026 | 1671 | 1.010 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 46 | 0.990 |
Why?
| | England | 13 | 2025 | 111 | 0.980 |
Why?
| | Retirement | 2 | 2025 | 35 | 0.960 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 76 | 0.960 |
Why?
| | United Kingdom | 14 | 2025 | 338 | 0.950 |
Why?
| | Gene Frequency | 19 | 2025 | 481 | 0.940 |
Why?
| | Poverty Areas | 3 | 2019 | 42 | 0.910 |
Why?
| | Emergency Service, Hospital | 12 | 2026 | 2313 | 0.870 |
Why?
| | Focus Groups | 5 | 2026 | 573 | 0.850 |
Why?
| | Sequence Deletion | 1 | 2025 | 193 | 0.850 |
Why?
| | Adaptation, Psychological | 8 | 2026 | 717 | 0.840 |
Why?
| | Genetics, Population | 11 | 2026 | 215 | 0.830 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 7 | 0.830 |
Why?
| | Medication Errors | 1 | 2024 | 83 | 0.820 |
Why?
| | Genome, Human | 6 | 2025 | 422 | 0.820 |
Why?
| | Residence Characteristics | 3 | 2021 | 378 | 0.800 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 205 | 0.760 |
Why?
| | Ligands | 15 | 2023 | 674 | 0.760 |
Why?
| | Multimorbidity | 1 | 2023 | 63 | 0.750 |
Why?
| | Complement C4 | 2 | 2025 | 26 | 0.730 |
Why?
| | Herpesviridae | 1 | 2022 | 22 | 0.730 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.730 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2025 | 676 | 0.720 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 1407 | 0.710 |
Why?
| | Minority Groups | 5 | 2024 | 282 | 0.700 |
Why?
| | Primates | 3 | 2019 | 132 | 0.700 |
Why?
| | Quality of Life | 16 | 2025 | 3192 | 0.700 |
Why?
| | Binge Drinking | 2 | 2021 | 44 | 0.700 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 150 | 0.690 |
Why?
| | Health Promotion | 6 | 2024 | 774 | 0.680 |
Why?
| | Patient Safety | 1 | 2024 | 349 | 0.670 |
Why?
| | Communicable Diseases | 1 | 2023 | 163 | 0.660 |
Why?
| | DNA Copy Number Variations | 6 | 2025 | 183 | 0.660 |
Why?
| | Cross-Sectional Studies | 17 | 2024 | 5872 | 0.660 |
Why?
| | Genetic Predisposition to Disease | 14 | 2025 | 2365 | 0.650 |
Why?
| | Male | 78 | 2026 | 72406 | 0.640 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 917 | 0.640 |
Why?
| | Major Histocompatibility Complex | 4 | 2025 | 229 | 0.640 |
Why?
| | Hearing Aids | 1 | 2021 | 93 | 0.630 |
Why?
| | Adult | 59 | 2026 | 40506 | 0.630 |
Why?
| | Seizures | 4 | 2019 | 477 | 0.630 |
Why?
| | Mortality | 2 | 2014 | 376 | 0.620 |
Why?
| | Censuses | 3 | 2017 | 35 | 0.620 |
Why?
| | Female | 84 | 2026 | 78376 | 0.620 |
Why?
| | Burns | 4 | 2026 | 377 | 0.610 |
Why?
| | Polymorphism, Single Nucleotide | 14 | 2026 | 2147 | 0.600 |
Why?
| | Waiting Lists | 3 | 2026 | 263 | 0.600 |
Why?
| | Aortic Aneurysm, Abdominal | 3 | 2017 | 167 | 0.600 |
Why?
| | Somatoform Disorders | 2 | 2016 | 35 | 0.590 |
Why?
| | Middle Aged | 53 | 2026 | 35928 | 0.580 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2023 | 364 | 0.570 |
Why?
| | Peptides | 4 | 2022 | 998 | 0.570 |
Why?
| | Intensive Care Units | 1 | 2024 | 916 | 0.550 |
Why?
| | Point Mutation | 3 | 2017 | 243 | 0.550 |
Why?
| | Receptors, KIR2DL4 | 3 | 2016 | 4 | 0.550 |
Why?
| | Hearing Loss | 1 | 2021 | 247 | 0.540 |
Why?
| | Pan troglodytes | 9 | 2017 | 63 | 0.540 |
Why?
| | Heterozygote | 1 | 2019 | 315 | 0.540 |
Why?
| | Motor Neuron Disease | 3 | 2025 | 21 | 0.530 |
Why?
| | Blood Vessel Prosthesis Implantation | 2 | 2022 | 228 | 0.520 |
Why?
| | Psoriasis | 3 | 2024 | 112 | 0.520 |
Why?
| | Language | 1 | 2020 | 323 | 0.520 |
Why?
| | Body Image | 4 | 2026 | 97 | 0.510 |
Why?
| | Genotyping Techniques | 4 | 2025 | 69 | 0.510 |
Why?
| | Health Status | 3 | 2025 | 836 | 0.510 |
Why?
| | Leukemia | 1 | 2019 | 245 | 0.500 |
Why?
| | Protein Binding | 10 | 2019 | 2276 | 0.490 |
Why?
| | Mucins | 1 | 2017 | 76 | 0.490 |
Why?
| | Rural Health Services | 3 | 2025 | 141 | 0.490 |
Why?
| | Linkage Disequilibrium | 10 | 2017 | 247 | 0.480 |
Why?
| | Quality Improvement | 4 | 2026 | 1291 | 0.480 |
Why?
| | Young Adult | 25 | 2026 | 14126 | 0.470 |
Why?
| | Blood Vessel Prosthesis | 2 | 2022 | 140 | 0.460 |
Why?
| | Energy Intake | 4 | 2026 | 500 | 0.460 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 41 | 0.460 |
Why?
| | Population Dynamics | 2 | 2018 | 158 | 0.460 |
Why?
| | Self Concept | 4 | 2026 | 253 | 0.450 |
Why?
| | Immunoglobulins | 4 | 2023 | 160 | 0.450 |
Why?
| | Weight Loss | 3 | 2019 | 837 | 0.450 |
Why?
| | Endovascular Procedures | 2 | 2022 | 384 | 0.450 |
Why?
| | Family Relations | 1 | 2015 | 88 | 0.440 |
Why?
| | Exons | 1 | 2016 | 358 | 0.430 |
Why?
| | Population | 1 | 2014 | 30 | 0.430 |
Why?
| | Longitudinal Studies | 11 | 2025 | 2947 | 0.420 |
Why?
| | Aged | 31 | 2026 | 25947 | 0.410 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 413 | 0.400 |
Why?
| | Wales | 5 | 2025 | 26 | 0.400 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.400 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 9 | 0.400 |
Why?
| | Terminally Ill | 1 | 2014 | 41 | 0.400 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 24 | 0.400 |
Why?
| | Sequence Analysis, DNA | 8 | 2025 | 824 | 0.400 |
Why?
| | Immunity, Innate | 7 | 2024 | 846 | 0.400 |
Why?
| | Behavior Therapy | 4 | 2023 | 299 | 0.380 |
Why?
| | Cell Line | 8 | 2019 | 2882 | 0.380 |
Why?
| | Malaria | 1 | 2013 | 73 | 0.380 |
Why?
| | Histocompatibility Testing | 4 | 2024 | 121 | 0.380 |
Why?
| | Overweight | 1 | 2017 | 609 | 0.370 |
Why?
| | T-Lymphocytes | 7 | 2026 | 1982 | 0.370 |
Why?
| | Stents | 2 | 2022 | 556 | 0.370 |
Why?
| | Empathy | 2 | 2024 | 182 | 0.360 |
Why?
| | Attitude of Health Personnel | 4 | 2025 | 1186 | 0.360 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1371 | 0.350 |
Why?
| | Mortality, Premature | 1 | 2011 | 14 | 0.350 |
Why?
| | Noninvasive Ventilation | 2 | 2025 | 62 | 0.350 |
Why?
| | Adolescent | 23 | 2026 | 22453 | 0.350 |
Why?
| | Intention | 3 | 2021 | 183 | 0.340 |
Why?
| | Infant Mortality | 2 | 2024 | 123 | 0.340 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2931 | 0.340 |
Why?
| | Cytomegalovirus | 3 | 2024 | 168 | 0.340 |
Why?
| | Thyroid Neoplasms | 2 | 2026 | 346 | 0.340 |
Why?
| | Life Expectancy | 1 | 2011 | 72 | 0.330 |
Why?
| | Life Style | 4 | 2017 | 479 | 0.330 |
Why?
| | Depression | 3 | 2023 | 1559 | 0.330 |
Why?
| | Emergency Medicine | 2 | 2024 | 261 | 0.330 |
Why?
| | Universities | 3 | 2021 | 452 | 0.330 |
Why?
| | Australia | 5 | 2024 | 286 | 0.330 |
Why?
| | Behcet Syndrome | 2 | 2021 | 19 | 0.320 |
Why?
| | Alcoholism | 1 | 2017 | 817 | 0.310 |
Why?
| | Health Behavior | 6 | 2025 | 786 | 0.310 |
Why?
| | Biological Evolution | 5 | 2019 | 488 | 0.310 |
Why?
| | Epitopes | 8 | 2019 | 485 | 0.310 |
Why?
| | Patient Compliance | 3 | 2025 | 589 | 0.310 |
Why?
| | Infant, Newborn | 9 | 2026 | 6434 | 0.300 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 2157 | 0.300 |
Why?
| | Cause of Death | 1 | 2011 | 472 | 0.290 |
Why?
| | Malnutrition | 2 | 2021 | 86 | 0.290 |
Why?
| | Patient Acceptance of Health Care | 3 | 2026 | 886 | 0.290 |
Why?
| | Recombination, Genetic | 2 | 2010 | 205 | 0.290 |
Why?
| | Health Personnel | 4 | 2025 | 748 | 0.290 |
Why?
| | Infant | 10 | 2026 | 10039 | 0.290 |
Why?
| | Models, Molecular | 5 | 2019 | 1619 | 0.290 |
Why?
| | Cytomegalovirus Infections | 2 | 2024 | 206 | 0.290 |
Why?
| | Meiosis | 1 | 2009 | 101 | 0.280 |
Why?
| | Antigens, CD | 5 | 2017 | 555 | 0.280 |
Why?
| | Newfoundland and Labrador | 5 | 2026 | 5 | 0.280 |
Why?
| | Urban Population | 1 | 2011 | 491 | 0.280 |
Why?
| | Life Change Events | 2 | 2019 | 147 | 0.270 |
Why?
| | Rural Population | 2 | 2018 | 650 | 0.270 |
Why?
| | Alcohol Drinking | 4 | 2021 | 826 | 0.270 |
Why?
| | Phylogeny | 12 | 2017 | 1019 | 0.260 |
Why?
| | Chronic Disease | 1 | 2014 | 1813 | 0.260 |
Why?
| | Genomics | 6 | 2025 | 836 | 0.260 |
Why?
| | Child | 13 | 2026 | 22657 | 0.260 |
Why?
| | Students | 3 | 2021 | 663 | 0.260 |
Why?
| | Object Attachment | 2 | 2019 | 48 | 0.260 |
Why?
| | China | 3 | 2024 | 269 | 0.260 |
Why?
| | Oceania | 2 | 2024 | 5 | 0.260 |
Why?
| | Income | 2 | 2019 | 202 | 0.260 |
Why?
| | Homozygote | 2 | 2025 | 199 | 0.260 |
Why?
| | Physicians | 2 | 2026 | 940 | 0.250 |
Why?
| | Caregivers | 5 | 2026 | 1049 | 0.250 |
Why?
| | Signal Transduction | 4 | 2019 | 5233 | 0.250 |
Why?
| | Immune System | 2 | 2019 | 179 | 0.250 |
Why?
| | Multigene Family | 3 | 2018 | 204 | 0.250 |
Why?
| | Papua New Guinea | 1 | 2026 | 10 | 0.240 |
Why?
| | Obesity | 2 | 2017 | 3082 | 0.240 |
Why?
| | Egypt | 2 | 2023 | 13 | 0.240 |
Why?
| | Centromere | 3 | 2025 | 59 | 0.240 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 5 | 0.240 |
Why?
| | Self-Management | 2 | 2019 | 201 | 0.240 |
Why?
| | Phenotype | 8 | 2024 | 3164 | 0.240 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2026 | 41 | 0.240 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 304 | 0.230 |
Why?
| | Animals | 29 | 2025 | 38109 | 0.230 |
Why?
| | Virus Activation | 2 | 2024 | 95 | 0.230 |
Why?
| | Codon | 2 | 2016 | 94 | 0.230 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2025 | 19 | 0.230 |
Why?
| | Thymus Gland | 2 | 2024 | 311 | 0.230 |
Why?
| | Acceptance and Commitment Therapy | 1 | 2026 | 30 | 0.230 |
Why?
| | Software | 4 | 2025 | 692 | 0.230 |
Why?
| | Patient Satisfaction | 4 | 2026 | 705 | 0.230 |
Why?
| | Industry | 1 | 2025 | 43 | 0.220 |
Why?
| | Patient Transfer | 2 | 2026 | 206 | 0.220 |
Why?
| | Smoking | 5 | 2019 | 1472 | 0.220 |
Why?
| | Hominidae | 2 | 2019 | 87 | 0.220 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2025 | 37 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 154 | 0.220 |
Why?
| | Rural Health | 1 | 2025 | 87 | 0.220 |
Why?
| | Body Mass Index | 1 | 2013 | 2438 | 0.220 |
Why?
| | Occupations | 1 | 2024 | 51 | 0.220 |
Why?
| | Capacity Building | 1 | 2025 | 62 | 0.210 |
Why?
| | Interpersonal Relations | 2 | 2019 | 400 | 0.210 |
Why?
| | Attitude to Health | 3 | 2019 | 436 | 0.210 |
Why?
| | Antigens, Neoplasm | 1 | 2026 | 272 | 0.210 |
Why?
| | Th17 Cells | 1 | 2025 | 101 | 0.210 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 21 | 0.210 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 137 | 0.210 |
Why?
| | Motivation | 2 | 2026 | 610 | 0.200 |
Why?
| | Surveys and Questionnaires | 9 | 2026 | 6053 | 0.200 |
Why?
| | Nutrition Therapy | 2 | 2025 | 37 | 0.200 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1209 | 0.200 |
Why?
| | Child, Preschool | 9 | 2026 | 11799 | 0.200 |
Why?
| | Phenylurea Compounds | 1 | 2024 | 112 | 0.200 |
Why?
| | Pedigree | 1 | 2025 | 514 | 0.200 |
Why?
| | Arabs | 2 | 2020 | 10 | 0.200 |
Why?
| | Cohort Studies | 8 | 2021 | 5965 | 0.200 |
Why?
| | Alopecia Areata | 1 | 2023 | 13 | 0.200 |
Why?
| | Quinolines | 2 | 2024 | 193 | 0.200 |
Why?
| | Immunity, Cellular | 1 | 2005 | 272 | 0.190 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 87 | 0.190 |
Why?
| | Parkinson Disease | 2 | 2020 | 600 | 0.190 |
Why?
| | Gene Dosage | 3 | 2021 | 148 | 0.190 |
Why?
| | Canada | 4 | 2025 | 428 | 0.190 |
Why?
| | Efficiency, Organizational | 2 | 2025 | 140 | 0.190 |
Why?
| | Cardiovascular Diseases | 3 | 2021 | 2171 | 0.190 |
Why?
| | Incidence | 5 | 2020 | 2883 | 0.190 |
Why?
| | Unemployment | 1 | 2022 | 42 | 0.190 |
Why?
| | Iran | 2 | 2020 | 44 | 0.190 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 186 | 0.190 |
Why?
| | Registries | 4 | 2021 | 2385 | 0.190 |
Why?
| | Time Factors | 11 | 2026 | 7183 | 0.190 |
Why?
| | Health Services Research | 1 | 2025 | 396 | 0.190 |
Why?
| | Leukocytes | 1 | 2004 | 295 | 0.190 |
Why?
| | Computational Biology | 2 | 2025 | 681 | 0.190 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1126 | 0.190 |
Why?
| | Colon | 1 | 2025 | 305 | 0.190 |
Why?
| | Sequence Alignment | 3 | 2021 | 368 | 0.180 |
Why?
| | Perception | 1 | 2025 | 377 | 0.180 |
Why?
| | Africa, Southern | 2 | 2021 | 6 | 0.180 |
Why?
| | Telomere | 4 | 2025 | 288 | 0.180 |
Why?
| | Colitis | 1 | 2025 | 280 | 0.180 |
Why?
| | Transplantation, Homologous | 5 | 2025 | 415 | 0.180 |
Why?
| | Social Stigma | 1 | 2024 | 172 | 0.180 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 28 | 0.180 |
Why?
| | Health | 1 | 2022 | 81 | 0.180 |
Why?
| | Age Factors | 5 | 2018 | 3335 | 0.170 |
Why?
| | Multilevel Analysis | 1 | 2021 | 36 | 0.170 |
Why?
| | Longevity | 1 | 2023 | 173 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 331 | 0.170 |
Why?
| | Eczema | 1 | 2022 | 66 | 0.170 |
Why?
| | New Zealand | 3 | 2018 | 54 | 0.170 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 13 | 0.170 |
Why?
| | Yersinia pestis | 1 | 2021 | 45 | 0.170 |
Why?
| | Interviews as Topic | 4 | 2026 | 901 | 0.170 |
Why?
| | Malaysia | 1 | 2020 | 16 | 0.170 |
Why?
| | Professional Practice Location | 1 | 2021 | 26 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 148 | 0.170 |
Why?
| | HLA-D Antigens | 1 | 2021 | 30 | 0.170 |
Why?
| | Nutritionists | 1 | 2021 | 24 | 0.170 |
Why?
| | HLA-DRB1 Chains | 3 | 2019 | 109 | 0.170 |
Why?
| | Nutritional Support | 1 | 2021 | 39 | 0.160 |
Why?
| | Plague | 1 | 2021 | 60 | 0.160 |
Why?
| | Physical Appearance, Body | 3 | 2024 | 4 | 0.160 |
Why?
| | Patient-Centered Care | 1 | 2026 | 544 | 0.160 |
Why?
| | Mindfulness | 1 | 2023 | 155 | 0.160 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 503 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2025 | 367 | 0.160 |
Why?
| | Clinical Protocols | 2 | 2019 | 282 | 0.160 |
Why?
| | Hearing Tests | 1 | 2020 | 51 | 0.160 |
Why?
| | Exercise | 5 | 2019 | 2201 | 0.160 |
Why?
| | Base Sequence | 4 | 2016 | 2191 | 0.160 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.150 |
Why?
| | Mentoring | 1 | 2023 | 166 | 0.150 |
Why?
| | Pregnancy | 6 | 2020 | 7191 | 0.150 |
Why?
| | Transportation | 1 | 2019 | 54 | 0.150 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 3 | 0.150 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 32 | 0.150 |
Why?
| | Protozoan Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Diet, Diabetic | 1 | 2019 | 33 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2025 | 484 | 0.150 |
Why?
| | Intestinal Mucosa | 1 | 2025 | 676 | 0.150 |
Why?
| | Hearing | 1 | 2020 | 132 | 0.150 |
Why?
| | B-Lymphocytes | 4 | 2017 | 877 | 0.150 |
Why?
| | Diabetic Foot | 1 | 2019 | 26 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 668 | 0.140 |
Why?
| | Bicycling | 1 | 2019 | 120 | 0.140 |
Why?
| | Phylogeography | 1 | 2019 | 55 | 0.140 |
Why?
| | Indians, North American | 2 | 2015 | 647 | 0.140 |
Why?
| | Diet | 4 | 2019 | 1275 | 0.140 |
Why?
| | Prevalence | 5 | 2019 | 2836 | 0.140 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 377 | 0.140 |
Why?
| | Sex Factors | 4 | 2019 | 2114 | 0.140 |
Why?
| | Parents | 2 | 2024 | 1403 | 0.140 |
Why?
| | Aggression | 1 | 2020 | 179 | 0.140 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 54 | 0.140 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 53 | 0.140 |
Why?
| | Indians, South American | 2 | 2009 | 23 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 988 | 0.140 |
Why?
| | Cluster Analysis | 2 | 2017 | 521 | 0.140 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 10 | 0.140 |
Why?
| | Syk Kinase | 1 | 2017 | 22 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 683 | 0.140 |
Why?
| | Middle East | 1 | 2017 | 18 | 0.130 |
Why?
| | Eye Diseases | 1 | 2019 | 94 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2024 | 484 | 0.130 |
Why?
| | Risk Factors | 12 | 2025 | 10792 | 0.130 |
Why?
| | Flow Cytometry | 7 | 2018 | 1173 | 0.130 |
Why?
| | Names | 1 | 2017 | 15 | 0.130 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 203 | 0.130 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 570 | 0.130 |
Why?
| | Binding Sites | 6 | 2015 | 1331 | 0.130 |
Why?
| | Polymerase Chain Reaction | 6 | 2017 | 1054 | 0.130 |
Why?
| | Walking | 2 | 2019 | 545 | 0.130 |
Why?
| | Lymphocyte Subsets | 3 | 2009 | 83 | 0.130 |
Why?
| | Genetic Testing | 4 | 2002 | 482 | 0.130 |
Why?
| | Pan paniscus | 1 | 2017 | 4 | 0.130 |
Why?
| | Contig Mapping | 1 | 2017 | 10 | 0.130 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 28 | 0.130 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 27 | 0.130 |
Why?
| | Osteosarcoma | 1 | 2018 | 76 | 0.130 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 862 | 0.130 |
Why?
| | Pongo | 1 | 2017 | 7 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2609 | 0.130 |
Why?
| | Air Pollution | 1 | 2021 | 327 | 0.130 |
Why?
| | Aorta, Abdominal | 1 | 2017 | 52 | 0.130 |
Why?
| | Models, Genetic | 4 | 2015 | 536 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 280 | 0.130 |
Why?
| | Alcoholic Beverages | 1 | 2017 | 31 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 100 | 0.130 |
Why?
| | Angiotensin II | 1 | 2017 | 97 | 0.130 |
Why?
| | Epilepsy | 2 | 2019 | 387 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 310 | 0.120 |
Why?
| | Antimicrobial Stewardship | 1 | 2019 | 130 | 0.120 |
Why?
| | Virus Diseases | 1 | 2019 | 216 | 0.120 |
Why?
| | Sarcoma, Ewing | 1 | 2018 | 103 | 0.120 |
Why?
| | Reference Standards | 1 | 2017 | 178 | 0.120 |
Why?
| | Anxiety | 3 | 2023 | 1110 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2024 | 8279 | 0.120 |
Why?
| | Allied Health Personnel | 1 | 2016 | 55 | 0.120 |
Why?
| | Logistic Models | 3 | 2021 | 2119 | 0.120 |
Why?
| | Open Reading Frames | 1 | 2017 | 132 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 590 | 0.120 |
Why?
| | Molecular Typing | 1 | 2016 | 21 | 0.120 |
Why?
| | Feeding Behavior | 2 | 2019 | 685 | 0.120 |
Why?
| | Placentation | 2 | 2016 | 53 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 489 | 0.120 |
Why?
| | Self Care | 2 | 2016 | 389 | 0.120 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 176 | 0.120 |
Why?
| | HIV-1 | 1 | 2022 | 896 | 0.120 |
Why?
| | Gene Expression | 4 | 2018 | 1490 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 946 | 0.120 |
Why?
| | Dissociative Disorders | 1 | 2015 | 30 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 79 | 0.110 |
Why?
| | Crohn Disease | 1 | 2019 | 260 | 0.110 |
Why?
| | Sf9 Cells | 1 | 2015 | 11 | 0.110 |
Why?
| | Age Distribution | 2 | 2018 | 403 | 0.110 |
Why?
| | Spodoptera | 1 | 2015 | 40 | 0.110 |
Why?
| | Sex Distribution | 2 | 2018 | 386 | 0.110 |
Why?
| | Baculoviridae | 1 | 2015 | 44 | 0.110 |
Why?
| | Case-Control Studies | 6 | 2024 | 3608 | 0.110 |
Why?
| | Chest Pain | 1 | 2016 | 100 | 0.110 |
Why?
| | Human Migration | 1 | 2015 | 26 | 0.110 |
Why?
| | Curriculum | 1 | 2022 | 1060 | 0.110 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 44 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2018 | 256 | 0.110 |
Why?
| | Research Report | 1 | 2015 | 87 | 0.110 |
Why?
| | Social Class | 1 | 2017 | 268 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.110 |
Why?
| | Insecta | 1 | 2015 | 74 | 0.110 |
Why?
| | Adolescent Behavior | 1 | 2020 | 501 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 224 | 0.110 |
Why?
| | Polynesia | 1 | 2014 | 3 | 0.110 |
Why?
| | Biological Assay | 1 | 2015 | 128 | 0.110 |
Why?
| | Isoantibodies | 1 | 1995 | 57 | 0.110 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 92 | 0.110 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1958 | 0.110 |
Why?
| | DNA | 3 | 2021 | 1464 | 0.100 |
Why?
| | Muscle Weakness | 1 | 2014 | 92 | 0.100 |
Why?
| | Protein Folding | 1 | 2015 | 279 | 0.100 |
Why?
| | Glucose | 1 | 2019 | 1049 | 0.100 |
Why?
| | Kidney Transplantation | 2 | 2003 | 704 | 0.100 |
Why?
| | Risk Reduction Behavior | 1 | 2015 | 226 | 0.100 |
Why?
| | Mammals | 1 | 2015 | 293 | 0.100 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 26 | 0.100 |
Why?
| | Prospective Studies | 7 | 2024 | 7997 | 0.100 |
Why?
| | Tissue Donors | 4 | 2024 | 424 | 0.100 |
Why?
| | Counseling | 1 | 2016 | 408 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2011 | 245 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2020 | 978 | 0.100 |
Why?
| | Species Specificity | 4 | 2017 | 574 | 0.100 |
Why?
| | Thinness | 1 | 2013 | 99 | 0.100 |
Why?
| | Cell Differentiation | 4 | 2024 | 2050 | 0.100 |
Why?
| | Seals, Earless | 1 | 2012 | 5 | 0.100 |
Why?
| | Interrupted Time Series Analysis | 2 | 2026 | 75 | 0.090 |
Why?
| | Exome | 1 | 2014 | 227 | 0.090 |
Why?
| | Genetics, Medical | 3 | 2019 | 23 | 0.090 |
Why?
| | DNA Primers | 4 | 2018 | 512 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 420 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2025 | 11695 | 0.090 |
Why?
| | Anxiety Disorders | 1 | 2016 | 373 | 0.090 |
Why?
| | Hepatitis C | 1 | 2015 | 254 | 0.090 |
Why?
| | Stress, Psychological | 2 | 2016 | 1153 | 0.090 |
Why?
| | Metagenomics | 1 | 2014 | 181 | 0.090 |
Why?
| | Graft Survival | 1 | 1995 | 526 | 0.090 |
Why?
| | Saliva | 1 | 2014 | 249 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2019 | 3890 | 0.090 |
Why?
| | Scotland | 1 | 2011 | 23 | 0.090 |
Why?
| | CD56 Antigen | 2 | 2009 | 35 | 0.090 |
Why?
| | Environment | 1 | 2013 | 305 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 284 | 0.090 |
Why?
| | Health Surveys | 1 | 2013 | 518 | 0.090 |
Why?
| | Graft Rejection | 1 | 1995 | 540 | 0.090 |
Why?
| | Self Efficacy | 1 | 2015 | 414 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1182 | 0.090 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.080 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 9 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2017 | 784 | 0.080 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 74 | 0.080 |
Why?
| | Internet | 1 | 2015 | 700 | 0.080 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 653 | 0.080 |
Why?
| | Immunoglobulin G | 1 | 1995 | 893 | 0.080 |
Why?
| | Triage | 2 | 2026 | 249 | 0.080 |
Why?
| | Graft vs Host Disease | 2 | 2025 | 264 | 0.080 |
Why?
| | Europe | 2 | 2021 | 412 | 0.080 |
Why?
| | North America | 2 | 2021 | 310 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 750 | 0.080 |
Why?
| | Cost-Benefit Analysis | 3 | 2025 | 636 | 0.080 |
Why?
| | Gene Conversion | 1 | 2009 | 7 | 0.080 |
Why?
| | Family | 1 | 2014 | 679 | 0.080 |
Why?
| | Gene Products, nef | 1 | 2009 | 12 | 0.080 |
Why?
| | Receptors, IgG | 2 | 2014 | 76 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 479 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2013 | 248 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1389 | 0.080 |
Why?
| | Self Report | 1 | 2014 | 873 | 0.070 |
Why?
| | Hospitalization | 2 | 2023 | 2434 | 0.070 |
Why?
| | Hospitals | 1 | 2014 | 732 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1099 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 102 | 0.070 |
Why?
| | Algorithms | 3 | 2024 | 1839 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 127 | 0.070 |
Why?
| | Africa | 3 | 2019 | 116 | 0.070 |
Why?
| | Nutritional Status | 2 | 2021 | 354 | 0.070 |
Why?
| | Insulin | 1 | 2019 | 2507 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1915 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2584 | 0.070 |
Why?
| | Homocysteine | 1 | 2008 | 151 | 0.070 |
Why?
| | Regression Analysis | 2 | 2021 | 1003 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 381 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1486 | 0.070 |
Why?
| | Breast Neoplasms | 4 | 2002 | 2456 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2642 | 0.060 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2004 | 26 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1416 | 0.060 |
Why?
| | HIV Infections | 1 | 2022 | 3154 | 0.060 |
Why?
| | Receptors, Fc | 1 | 2007 | 55 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 396 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2025 | 947 | 0.060 |
Why?
| | Neoplasms | 2 | 2017 | 2884 | 0.060 |
Why?
| | Genetic Counseling | 3 | 2002 | 81 | 0.060 |
Why?
| | Risk | 3 | 2019 | 911 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4569 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2026 | 29 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2007 | 214 | 0.060 |
Why?
| | HLA-DR Antigens | 2 | 2006 | 220 | 0.060 |
Why?
| | Genetic Loci | 2 | 2019 | 261 | 0.060 |
Why?
| | Trinidad and Tobago | 2 | 2002 | 5 | 0.060 |
Why?
| | Norway | 1 | 2025 | 45 | 0.060 |
Why?
| | Ireland | 1 | 2025 | 32 | 0.060 |
Why?
| | Equivalence Trials as Topic | 1 | 2025 | 36 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 387 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2925 | 0.060 |
Why?
| | Mice | 5 | 2025 | 18365 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2019 | 114 | 0.060 |
Why?
| | INDEL Mutation | 1 | 2025 | 19 | 0.060 |
Why?
| | Palliative Care | 1 | 2014 | 1008 | 0.060 |
Why?
| | Kinetochores | 1 | 2025 | 52 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2017 | 4155 | 0.060 |
Why?
| | Stroke | 1 | 2014 | 1258 | 0.050 |
Why?
| | Recurrence | 2 | 2021 | 1135 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2025 | 3125 | 0.050 |
Why?
| | Models, Statistical | 2 | 2019 | 682 | 0.050 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3550 | 0.050 |
Why?
| | Histocompatibility | 1 | 2003 | 21 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 183 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 650 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5997 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2024 | 132 | 0.050 |
Why?
| | Prognosis | 2 | 2025 | 4293 | 0.050 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 405 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 157 | 0.050 |
Why?
| | Granzymes | 1 | 2023 | 49 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 444 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 324 | 0.050 |
Why?
| | Lymphocytes | 1 | 2005 | 382 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 460 | 0.050 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.050 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 27 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 126 | 0.050 |
Why?
| | Africa, Western | 1 | 2002 | 21 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2002 | 41 | 0.050 |
Why?
| | Pakistan | 1 | 2002 | 78 | 0.050 |
Why?
| | Bangladesh | 1 | 2002 | 62 | 0.050 |
Why?
| | HLA-DQ Antigens | 1 | 2002 | 173 | 0.040 |
Why?
| | Pandemics | 2 | 2021 | 1695 | 0.040 |
Why?
| | Risk Assessment | 4 | 2019 | 3676 | 0.040 |
Why?
| | Cloning, Molecular | 2 | 2014 | 541 | 0.040 |
Why?
| | Software Design | 1 | 2021 | 25 | 0.040 |
Why?
| | India | 1 | 2002 | 218 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 39 | 0.040 |
Why?
| | Cytokines | 2 | 2025 | 2065 | 0.040 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 118 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 63 | 0.040 |
Why?
| | Thailand | 1 | 2001 | 18 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 359 | 0.040 |
Why?
| | Odds Ratio | 2 | 2017 | 1077 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2021 | 92 | 0.040 |
Why?
| | Twins | 1 | 2001 | 156 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 962 | 0.040 |
Why?
| | Geography | 1 | 2021 | 203 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2021 | 333 | 0.040 |
Why?
| | Cholesterol, HDL | 1 | 2021 | 200 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 685 | 0.040 |
Why?
| | Length of Stay | 1 | 2026 | 1337 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 357 | 0.040 |
Why?
| | Genetic Markers | 1 | 2001 | 331 | 0.040 |
Why?
| | Breathing Exercises | 1 | 2019 | 21 | 0.040 |
Why?
| | Leadership | 1 | 2024 | 409 | 0.040 |
Why?
| | Respiratory Muscles | 1 | 2019 | 36 | 0.040 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2019 | 29 | 0.040 |
Why?
| | Electric Impedance | 1 | 2019 | 111 | 0.040 |
Why?
| | Deglutition | 1 | 2019 | 72 | 0.040 |
Why?
| | Patient Acuity | 1 | 2019 | 47 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 286 | 0.040 |
Why?
| | Communication | 1 | 2026 | 967 | 0.040 |
Why?
| | Hospital Units | 1 | 2019 | 32 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 744 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 37 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2019 | 51 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 32 | 0.040 |
Why?
| | Group Processes | 1 | 2019 | 64 | 0.040 |
Why?
| | Celiac Disease | 1 | 2002 | 308 | 0.040 |
Why?
| | Ketones | 1 | 2019 | 53 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2019 | 65 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2019 | 89 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1137 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 66 | 0.040 |
Why?
| | Western Australia | 1 | 2018 | 8 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 4099 | 0.040 |
Why?
| | Triglycerides | 1 | 2021 | 521 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 97 | 0.040 |
Why?
| | Cough | 1 | 2019 | 124 | 0.040 |
Why?
| | Chromosome Mapping | 2 | 2014 | 510 | 0.040 |
Why?
| | Disease Progression | 2 | 2017 | 2852 | 0.030 |
Why?
| | Posture | 1 | 2019 | 196 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 415 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2021 | 378 | 0.030 |
Why?
| | Narration | 1 | 2019 | 75 | 0.030 |
Why?
| | Ankle Brachial Index | 1 | 2018 | 41 | 0.030 |
Why?
| | Biomarkers | 2 | 2021 | 4275 | 0.030 |
Why?
| | Parenting | 1 | 2022 | 318 | 0.030 |
Why?
| | Body Height | 1 | 2019 | 202 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 970 | 0.030 |
Why?
| | Particulate Matter | 1 | 2021 | 347 | 0.030 |
Why?
| | Deglutition Disorders | 1 | 2019 | 147 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 189 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 539 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2017 | 12 | 0.030 |
Why?
| | Demography | 2 | 2013 | 288 | 0.030 |
Why?
| | Collagen Type III | 1 | 2017 | 18 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1169 | 0.030 |
Why?
| | Butyrophilins | 1 | 2017 | 5 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 7 | 0.030 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 20 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2017 | 53 | 0.030 |
Why?
| | Gorilla gorilla | 1 | 2017 | 18 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 185 | 0.030 |
Why?
| | Lymphocyte Count | 3 | 2002 | 164 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 629 | 0.030 |
Why?
| | Elastin | 1 | 2017 | 79 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 402 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2017 | 94 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 1026 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2017 | 132 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 129 | 0.030 |
Why?
| | Proteolysis | 1 | 2017 | 173 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5417 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 121 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 175 | 0.030 |
Why?
| | Cross Infection | 1 | 2019 | 262 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 893 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 409 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1888 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1504 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 249 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 326 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1524 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 18 | 0.030 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 101 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 80 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 7 | 0.030 |
Why?
| | Nursing Staff | 1 | 2016 | 41 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 433 | 0.030 |
Why?
| | Americas | 1 | 2015 | 26 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 93 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 732 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 48 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 169 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 56 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 223 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 627 | 0.030 |
Why?
| | Vascular Remodeling | 1 | 2017 | 205 | 0.030 |
Why?
| | Attitude | 1 | 2017 | 261 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 249 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 1129 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 28 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 949 | 0.030 |
Why?
| | Fruit | 1 | 2015 | 152 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 430 | 0.030 |
Why?
| | Smoking Prevention | 1 | 2015 | 166 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 365 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 59 | 0.030 |
Why?
| | Vegetables | 1 | 2015 | 170 | 0.030 |
Why?
| | Social Support | 1 | 2019 | 652 | 0.030 |
Why?
| | Patient Care Team | 1 | 2000 | 689 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 546 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 261 | 0.030 |
Why?
| | Hypoglycemia | 1 | 2019 | 477 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 255 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 294 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 780 | 0.030 |
Why?
| | Models, Psychological | 1 | 2015 | 299 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 30 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 306 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 88 | 0.030 |
Why?
| | Hepacivirus | 1 | 2015 | 243 | 0.030 |
Why?
| | Inflammation | 1 | 2025 | 2880 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2015 | 373 | 0.020 |
Why?
| | Reproduction | 1 | 2015 | 207 | 0.020 |
Why?
| | Transplant Recipients | 1 | 2015 | 180 | 0.020 |
Why?
| | United States | 2 | 2023 | 15988 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2015 | 268 | 0.020 |
Why?
| | Asia | 2 | 2003 | 70 | 0.020 |
Why?
| | Cultural Competency | 1 | 2014 | 93 | 0.020 |
Why?
| | Ultrasonography | 1 | 2017 | 770 | 0.020 |
Why?
| | Lung | 2 | 2019 | 4109 | 0.020 |
Why?
| | Ursidae | 1 | 2012 | 8 | 0.020 |
Why?
| | Smad Proteins | 1 | 2012 | 43 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 706 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1031 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 57 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 371 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 212 | 0.020 |
Why?
| | Genome | 1 | 2014 | 306 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 1975 | 332 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 1000 | 0.020 |
Why?
| | Family Practice | 1 | 1975 | 404 | 0.020 |
Why?
| | Feces | 1 | 2015 | 513 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 374 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 35 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2015 | 439 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1992 | 105 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2016 | 1095 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3415 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 52 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2013 | 366 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 438 | 0.020 |
Why?
| | Models, Biological | 2 | 2016 | 1822 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 35 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1098 | 0.020 |
Why?
| | Twins, Dizygotic | 2 | 2001 | 109 | 0.020 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2012 | 139 | 0.020 |
Why?
| | Twins, Monozygotic | 2 | 2001 | 134 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 311 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 226 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 381 | 0.020 |
Why?
| | Culture | 1 | 2011 | 125 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1990 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 60 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2499 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 116 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 392 | 0.020 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 35 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 369 | 0.020 |
Why?
| | Pyridoxine | 1 | 2008 | 37 | 0.020 |
Why?
| | Personality Inventory | 1 | 2008 | 134 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 266 | 0.020 |
Why?
| | Aging | 1 | 2019 | 1966 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 181 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 493 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2008 | 127 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 699 | 0.020 |
Why?
| | Hemodynamics | 1 | 2012 | 1121 | 0.020 |
Why?
| | Folic Acid | 1 | 2008 | 199 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 906 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 302 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 8 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2007 | 148 | 0.010 |
Why?
| | Rabbits | 1 | 2007 | 648 | 0.010 |
Why?
| | Microbiota | 1 | 2014 | 781 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 23 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2005 | 72 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 780 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 88 | 0.010 |
Why?
| | Microspheres | 1 | 2005 | 142 | 0.010 |
Why?
| | Cell Separation | 1 | 2005 | 307 | 0.010 |
Why?
| | Genetic Techniques | 1 | 2004 | 67 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2005 | 322 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 50 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1258 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1167 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2002 | 16 | 0.010 |
Why?
| | HLA-DQ beta-Chains | 1 | 2002 | 57 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 354 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 265 | 0.010 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 22 | 0.010 |
Why?
| | Utah | 1 | 2002 | 81 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1721 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 280 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 529 | 0.010 |
Why?
| | Genes, BRCA1 | 1 | 2000 | 45 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2000 | 166 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 17101 | 0.010 |
Why?
| | BRCA2 Protein | 1 | 2000 | 67 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 847 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1540 | 0.010 |
Why?
| | Ambulatory Care Facilities | 1 | 2000 | 266 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2000 | 1311 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2000 | 463 | 0.010 |
Why?
| | Hospital Departments | 1 | 1975 | 9 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2000 | 853 | 0.010 |
Why?
| | Receptors, Leukotriene B4 | 1 | 1992 | 7 | 0.010 |
Why?
| | SRS-A | 1 | 1992 | 17 | 0.010 |
Why?
| | Dicarboxylic Acids | 1 | 1992 | 11 | 0.010 |
Why?
| | Receptors, Leukotriene | 1 | 1992 | 13 | 0.010 |
Why?
| | Leukotriene E4 | 1 | 1992 | 24 | 0.010 |
Why?
| | Propionates | 1 | 1992 | 39 | 0.010 |
Why?
| | Transcription Factors | 1 | 2000 | 1742 | 0.010 |
Why?
| | Cysteine | 1 | 1992 | 210 | 0.010 |
Why?
| | Muscle Contraction | 1 | 1992 | 429 | 0.000 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|